Adaptive Trial Design
An adaptive trial design allows pre-specified modifications to the trial based on interim data—such as sample size re-estimation, stopping for futility or efficacy, dropping ineffective arms, or shifting randomization ratios toward better-performing treatments. Developed systematically in the 1990s–2000s by statisticians like Pocock and Jennison, and formalized by the FDA in 2019, adaptive designs accelerate drug development, reduce exposure to ineffective treatments, and improve efficiency without inflating false-positive rates when properly executed.
Registre font
Les citacions es copien textualment del registre font del mètode. No s'infereix cap verificació a nivell de reclam d'elles.
- Pocock, S. J. (2005). Current issues in the design and interpretation of clinical trials. BMJ, 330(7500), 1118–1121. · URL
- Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., ... & Wason, J. (2018). Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine, 16(1), 29. · DOI 10.1186/s12916-018-1017-7
- FDA (2019). Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. US Food and Drug Administration. · URL
Reclamacions curades
Les reclamacions s'han persistit al registre de proves, cadascuna amb la seva pròpia avaluació.
Aquesta vista no inventa una avaluació de reclam quan el registre no en té cap.
Mètodes relacionats
Generat a partir del gràfic de mètodes i mostrat com a relacions suggerides per la màquina; no s'infereix cap reclamació d'evidència.